Barr Gets Go-Ahead For Generic Yasmin
This article was originally published in The Pink Sheet Daily
Executive Summary
ANDA approval comes two months after court ruling on Bayer contraceptive.
You may also be interested in...
Mylan Will Begin Marketing New Generic Oral Contraceptive Portfolio In 2010
Mylan Pharmaceuticals will enter the generic women's health care market with a portfolio of 22 oral contraceptive products acquired through a development and supply agreement with India-based Famy Care
Mylan Will Begin Marketing New Generic Oral Contraceptive Portfolio In 2010
Mylan Pharmaceuticals will enter the generic women's health care market with a portfolio of 22 oral contraceptive products acquired through a development and supply agreement with India-based Famy Care
Court Finds Bayer’s Yasmin Oral Contraceptive Patent Is Invalid
A district court ruling against Bayer’s oral contraceptive patent opens the way for Barr to launch a generic version of Yasmin.